Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Corbus Pharmaceuticals Holdings (CRBP) presented Phase 1b CANYON-1 obesity data showing 5% mean weight loss with CRB-913 at 12 weeks. The placebo-controlled study enrolled 254 non-diabetic adults with obesity. Mean weight loss was 2.8%, 3.3% and 5.0% at 20 mg, 40 mg and 60 mg, respectively, versus 0.0% with placebo; all comparisons had p<0.0001. Waist circumference and body mass index also declined, with no weight-loss plateau observed.
Safety results included no serious treatment-related adverse events and no serious or severe psychiatric events. However, four participants had serious treatment-emergent events, meaning events arising during treatment regardless of cause. Adverse-event discontinuations were 8.3% across all cohorts, including placebo, and 12.9% at 60 mg. Corbus plans FDA discussions on the data and development plans and is evaluating potential combinations with GLP-1 therapies.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointWeek-12 mean weight loss was 2.8%, 3.3% and 5.0% at 20/40/60 mg versus 0.0% with placebo; all p<0.0001.
- Minor pointNo weight-loss plateau was observed at any CRB-913 dose during the study.
- Minor pointWaist circumference changed by -3.03/-3.04/-3.94 cm at 20/40/60 mg versus -0.84 cm with placebo.
- Minor pointBody mass index changed by -2.81%/-3.34%/-4.99% at 20/40/60 mg versus -0.06% with placebo.
- Minor pointAll 60 mg study completers lost weight; 44.4% lost at least 5.0% from baseline.
7 minor points
- Minor pointWeight loss above 7.5% occurred in 6.7% of 60 mg study completers; the highest recorded loss was 13.4%.
- Minor pointNo serious treatment-related adverse events occurred in any cohort.
- Minor pointNo serious or severe psychiatric events or suicidality were reported; all psychiatric adverse events resolved.
- Minor pointGastrointestinal events were all mild or moderate, with no serious or severe cases.
- Minor pointVomiting, nausea and constipation were less frequent and milder than published oral GLP-1 results, Corbus said.
- Minor point. Forward-looking: it has not happened yet and may not happen.FDA discussions on CRB-913 data and development plans are planned by Corbus.
- Minor point. Forward-looking: it has not happened yet and may not happen.Combination development with GLP-1 therapies is being evaluated by Corbus.
Negative
- Moderate pointAdverse-event discontinuations were 3.1%/13.1%/12.9% at 20/40/60 mg versus 4.5% with placebo; overall, 8.3%.
- Minor pointTreatment-emergent adverse events affected 60.0%/73.8%/72.6% at 20/40/60 mg versus 42.4% with placebo.
- Minor pointSerious treatment-emergent events affected 2/1/1 participants at 20/40/60 mg versus none with placebo.
- Minor pointSevere treatment-emergent events affected 3/2/1 participants at 20/40/60 mg versus none with placebo.
- Minor pointTreatment-related adverse events affected 41.5%/55.7%/53.2% at 20/40/60 mg versus 21.2% with placebo.
10 minor points
- Minor pointOne severe treatment-related event occurred in the 40 mg cohort, affecting 1.6% of participants.
- Minor pointAll-cause treatment discontinuations were 15.4%/26.2%/25.8% at 20/40/60 mg versus 18.2% with placebo.
- Minor pointModerate depressive symptoms occurred in one 60 mg participant, or 1.6%, versus none in other cohorts.
- Minor pointAnxiety affected 3.1%/8.2%/4.8% at 20/40/60 mg versus 4.5% with placebo.
- Minor pointMild irritability affected 15 CRB-913 participants (8%); it resolved spontaneously without affecting daily function.
- Minor pointNausea affected 15.4%/26.2%/22.6% at 20/40/60 mg versus 4.5% with placebo.
- Minor pointDiarrhea affected 21.5%/26.2%/22.6% at 20/40/60 mg versus 3.0% with placebo.
- Minor pointVomiting affected 4.6%/8.2%/1.6% at 20/40/60 mg versus none with placebo.
- Minor pointConstipation affected 4.6%/1.6%/4.8% at 20/40/60 mg versus 3.0% with placebo.
- Minor pointGastrointestinal adverse events caused treatment discontinuation in two CRB-913 participants and one placebo participant.
Key Figures
- Mean weight loss
- 5%
- At 60 mg after 12 weeks
- P-value vs. placebo
- <0.0001
- For each of the 20 mg, 40 mg, and 60 mg cohorts
- Study enrollment
- 254 participants
- CANYON-1 Phase 1b study
- At least 5% weight loss
- 44.4%
- Participants completing the study at 60 mg
- Discontinuation due to adverse events
- 8.3%
- Across all study cohorts
- Serious or severe psychiatric adverse events
- 0 reported
- CANYON-1 study
Previous Clinical trial Reports
-
Earlier CANYON-1 topline reported 5% week-12 loss at 60 mg; poster adds detailed safety.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
placebo-controlled medical
glp-1 medical
teae medical
mmrm technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of
5% at 60 mg after 12 weeks with no plateauing observed - Corresponding significant reductions were also seen in waist circumference and body mass index (BMI)
- Treatment-emergent psychiatric adverse events (AEs) were infrequent, mostly mild, and in line with published GLP-1 data
- No serious or severe psychiatric AEs were reported, including no cases of severe or serious suicidality or depression
- Vomiting, nausea, and constipation occurred at lower rates and were milder than those reported in published studies of oral GLP-1s
NORWOOD, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, announced today that additional data from the CANYON-1 Phase 1b obesity study were presented in a poster at ObesityWeek® 2026.
The data demonstrated statistically significant and clinically meaningful weight loss at all three doses of CRB-913, with the highest dose of 60 mg achieving a mean weight loss of
“We’re pleased to share the CANYON-1 trial data at ObesityWeek®. While the rise of incretin-based therapies has been remarkable, a significant number of people either do not adequately respond to or cannot tolerate these therapies, with more than
Study Design
The CANYON-1 Phase 1b clinical trial was a 16-week, double-blind, placebo-controlled, dose-ranging study that enrolled 254 obese, non-diabetic adult participants at 15 investigational sites in the United States (NCT07310901). The trial included three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once daily, as well as a placebo cohort (randomization ratio of 1:1:1:1). A dose titration regimen was used, with all participants receiving CRB-913 starting at 20 mg/day and those assigned to the higher-dose cohorts titrating up every two weeks to either 40 mg/day or 60 mg/day, depending on their assigned cohort. Participants were dosed for 12 weeks and followed for an additional 4 weeks.
Efficacy
CRB-913 demonstrated rapid, statistically significant, and clinically meaningful weight loss at all dose levels, with no evidence of plateauing at any of the doses. Weight loss response rates were significantly higher across all three CRB-913 cohorts compared to the placebo cohort.
| CRB-913 | ||||
| Cohort | Placebo (n = 66) | 20 mg (n = 65) | 40 mg (n = 61) | 60 mg (n = 62) |
| LS mean weight loss from baseline at week 12, %1 | ||||
| LS mean weight loss at week 12, % (placebo-adjusted)1 | NA | |||
| p-value vs. placebo | NA | <0.0001 | <0.0001 | <0.0001 |
| Change in waist circumference from baseline, cm | -0.84 | -3.03 | -3.04 | -3.94 |
| p-value | 0.21 | <0.0001 | <0.0001 | <0.0001 |
| BMI percent change from baseline | -0.06 | -2.81 | -3.34 | -4.99 |
| p-value | 0.89 | <0.0001 | <0.0001 | <0.0001 |
1 Efficacy estimand. The LS means and p-values were derived using a mixed model for repeated measures (MMRM), with percent change from baseline as the dependent variable; sex, treatment group, visit, and the treatment group-by-visit interaction as categorical fixed effects; and baseline weight as a covariate. An unstructured covariance matrix was used.
All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with
Safety
CRB-913 was safe and well tolerated. The treatment discontinuation rate due to AEs across all study cohorts was low at
| CRB-913 | |||||
| Safety measure | Placebo (n = 66) | 20 mg (n = 65) | 40 mg (n = 61) | 60 mg (n = 62) | Total (N = 254) |
| Any TEAE, n (%) | 28 (42.4) | 39 (60.0) | 45 (73.8) | 45 (72.6) | 157 (61.8) |
| Severe TEAE | 0 (0.0) | 3 (4.6) | 2 (3.3) | 1 (1.6) | 6 (2.4) |
| Severe psychiatric TEAE | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Severe gastrointestinal TEAE | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Serious TEAE | 0 (0.0) | 2 (3.1) | 1 (1.6) | 1 (1.6) | 4 (1.6) |
| Any TRAE, n (%) | 14 (21.2) | 27 (41.5) | 34 (55.7) | 33 (53.2) | 108 (42.5) |
| Severe TRAE | 0 (0.0) | 0 (0.0) | 1 (1.6) | 0 (0.0) | 1 (0.4) |
| Serious TRAE | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Treatment discontinuation for any reason, n (%) | 12 (18.2) | 10 (15.4) | 16 (26.2) | 16 (25.8) | 54 (21.3) |
| Treatment discontinuation due to an AE, n (%) | 3 (4.5) | 2 (3.1) | 8 (13.1) | 8 (12.9) | 21 (8.3) |
Psychiatric Adverse Events
Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe psychiatric AEs were reported.
| CRB-913 | ||||
| Adverse event, n (%) | Placebo (n = 66) | 20 mg (n = 65) | 40 mg (n = 61) | 60 mg (n = 62) |
| Suicidality | 0 | 0 | 0 | 0 |
| Depressive symptoms | 0 | 0 | 0 | 1 ( (moderate) |
| Anxiety | 3 ( | 2 ( | 5 ( | 3 ( |
Fifty percent of the psychiatric AEs occurred within the first 28 days, a pattern similar to that seen with GLP-1 analogs. No cases of suicidal ideation or serious or severe depression were observed. Psychiatric AEs did not appear to be dose-related; rates of depression and anxiety were in line with those reported in published GLP-1 studies. Only one of the 188 participants receiving CRB-913 reported transient, moderate depressive symptoms, a rate that is in line with published GLP-1 data. A total of 15 participants (
Gastrointestinal Adverse Events
Treatment-emergent gastrointestinal AEs were all mild or moderate, with no serious or severe events.
| CRB-913 | ||||
| Adverse event, n (%) | Placebo (n = 66) | 20 mg (n = 65) | 40 mg (n = 61) | 60 mg (n = 62) |
| Vomiting | 0 | 3 ( | 5 ( | 1 ( |
| Nausea | 3 ( | 10 ( | 16 ( | 14 ( |
| Constipation | 2 ( | 3 ( | 1 ( | 3 ( |
| Diarrhea | 2 ( | 14 ( | 16 ( | 14 ( |
Vomiting, nausea, and constipation occurred at lower rates and were less severe than those reported in published studies of oral GLP-1s. Treatment discontinuations due to gastrointestinal AEs occurred in only three participants (two on CRB-913 and one on placebo).
Next Steps
Corbus plans to engage with the FDA to discuss the data and the development plans for CRB-913. The Company is also evaluating the potential for CRB-913 in combination with GLP-1 therapies.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes SUTA-E (sutantatug envedotin), a next-generation antibody-drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered, highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn, and Facebook.
Forward-Looking Statements
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the potential benefits and development of CRB-913, future clinical studies and regulatory discussions, potential combination therapies, development timing and funding. They reflect current expectations and assumptions and are subject to risks and uncertainties that could cause actual outcomes to differ materially. These include the possibility that early clinical findings will not be reproduced in larger or longer studies; additional safety findings or changes following further analysis; delays in clinical or regulatory activities; and the availability and terms of financing or partnering arrangements. Further risks are described under the heading “Risk Factors” in Corbus most recent Annual Report on Form-10-K and subsequent Quarterly Reports on Form10-Q filed with the Securities and Exchange Commission. Forward-looking statements apply only as of the date of this release. Corbus does not undertake to update them except as required by law.
Investor Contacts
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
Media Contact
Liz Melone
Founder and Principal
Melone Communications, LLC
liz@melonecomm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How was Corbus's CANYON-1 CRB-913 trial designed?
CANYON-1 was a 16-week, double-blind, placebo-controlled, dose-ranging study at 15 United States sites. Participants were randomized 1:1:1:1 to placebo or once-daily oral CRB-913 at 20 mg, 40 mg or 60 mg. Active treatment started at 20 mg/day, with higher-dose groups increasing every two weeks. Dosing lasted 12 weeks, followed by four weeks of follow-up.